Abstract
Objective
The aim of our study was to evaluate the serum levels of CA19-9 in patients with non-small cell lung cancer (NSCLC) and to analyze the relationship between serum levels of CA19-9 and metastasis.
Methods
Serum levels of CA19-9 in 1200 NSCLC patients from February 2006 to August 2011 were evaluated retrospectively. The relationship between serum levels of CA19-9 and sites of metastasis were analyzed.
Results
Of the 1200 patients, 528 were stage IV and the positive rate of CA19-9 was 32% (169 cases) and 288 stage III, positive rate 20% (58 cases); 144 stage II, positive rate 12% (17 cases); 240 stage I, positive rate 3% (7 cases). There were statistical differences from stage I to stage IV (P < 0.01). The total positive rate in the 1200 cases was 21%. Furthermore, of the 528 stage IV cases, 350 had bone metastasis and the positive rate of CA19-9 was 43% (150 cases) in bone metastatic cases. In turn, in CA19-9 positive patients (169 cases) of stage IV, the positive rate of bone metastasis was 89% (150/169). There was no statistical difference of positive rate of CA19-9 between adenocarcinoma and squamous carcinoma (P > 0.05).
Conclusion
Positive rate of CA19-9 increases accordingly from stage I to stage IV. The serum levels of CA19-9 may be as an indicator for metastases in patients with NSCLC, especially for bone metastasis in stage IV diseases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Guo QS, Sun YL. Treatment of non-small cell lung cancer: Principles of comprehensive treatment of non-small cell lung cancer. Shandong Med J (Chinese), 2011, 21: 101–102.
Kondo N, Murakami Y, Uemura K, et al. Prognostic impact of perioperative serum CA19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol, 2010, 17: 2321–2329.
Park IJ, Choi GS, Jun SH. Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer. Anticancer Res, 2009, 29: 4303–4308.
Hatate K, Yamashita K, Hirai K, et al. Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9. Oncol Rep, 2008, 20: 737–743.
Hwang GI, Yoo CH, Sohn BH, et al. Predictive value of preoperative serum CEA, CA19-9 and CA125 levels for peritoneal metastasis in patients with gastric carcinoma. Cancer Res Treat, 2004, 36: 178–181.
Yang XQ, Wang D, Li ZP, et al. Clinical significance of multiple tumor marker protein chip in monitoring the recurrence, progression and metastasis of lung cancer. Chin J Lung Cancer (Chinese), 2007, 10: 296–300.
Fujita J, Dobashi N, Ohtsuki Y, et al. Detection of large molecular weight cytokeratin 8 as carrier protein of CA19-9 in non-small-cell lung cancer cell lines. Br J Cancer, 1999, 81: 769–773.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, X., Shan, G., Zhang, S. et al. Serum levels of CA19-9 may be as an indicator for metastases in patients with non-small cell lung cancer. Chin. -Ger. J. Clin. Oncol. 10, 692–694 (2011). https://doi.org/10.1007/s10330-011-0914-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-011-0914-4